Arbor Biotechnologies and Chiesi Seal Over $2 Billion Deal for Gene Editing Rare Disease Therapies

Arbor Biotechnologies has entered a landmark partnership with Chiesi Group, granting exclusive global rights and up to $2.1 billion in payments for the development and commercialization of ABO-101 gene editing therapy targeting primary hyperoxaluria type 1. The deal includes an option for additional rare disease targets and leverages Arbor’s advanced knockout and reverse transcriptase editing platforms. This collaboration marks Chiesi’s first foray into gene editing and rare disease gene therapies.